DexCom, Inc. (DXCM) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

DexCom, Inc. (DXCM) Healthcare & Pipeline Overview

DexCom, Inc. pioneers continuous glucose monitoring (CGM) technology, offering advanced systems like DexCom G6 and G7 for diabetes management. With a focus on innovation and patient-centric solutions, DexCom competes in the dynamic medical device landscape, serving both individual patients and healthcare providers globally.

What Is the Investment Thesis for DXCM?

DexCom's investment thesis rests on the increasing adoption of CGM technology for diabetes management. The company's innovative products, such as the DexCom G6 and upcoming G7, offer significant advantages over traditional blood glucose monitoring methods. With a profit margin of 19.3% and a gross margin of 61.8%, DexCom demonstrates strong financial performance. Key growth catalysts include expanding market penetration in both the United States and international markets, as well as the introduction of new products and features. The company's collaboration with Verily Life Sciences could lead to the development of groundbreaking glucose monitoring technologies. Potential risks include increased competition from other medical device companies and regulatory challenges. The company's P/E ratio is 32.63, and its beta is 1.56.

Based on FMP financials and quantitative analysis

DXCM Key Highlights

Market Cap of $31.9B reflects DexCom's strong position in the CGM market.

• Profit Margin of 19.3% indicates efficient operations and strong pricing power.
• Gross Margin of 61.8% demonstrates the value of DexCom's technology and brand.
• DexCom G6 and G7 systems are driving adoption of continuous glucose monitoring.
• Collaboration with Verily Life Sciences positions DexCom for future innovation in glucose monitoring.

Who Are DXCM's Competitors?

DXCM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DXCM's Key Strengths?

Innovative CGM technology

• Strong brand reputation
• Established market presence
• High gross margins

What Are DXCM's Weaknesses?

Reliance on a single product category

• High R&D expenses
• Vulnerability to regulatory changes
• Dependence on third-party manufacturers

What Could Drive DXCM Stock Higher?

DXCM catalyst: Launch of DexCom G7, a next-generation CGM system with improved accuracy and ease of use.

• Expansion of DexCom's international presence, particularly in Europe and Asia.
• Integration of DexCom's CGM data with various digital health platforms and applications.
• Development of new features and functionalities for DexCom's CGM systems.
• Strategic partnerships and acquisitions to expand DexCom's capabilities and market reach.

What Are the Key Risks for DXCM?

Rich valuation — a P/E of 32.63 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $12.2M recently.
• Increased competition from other medical device companies in the CGM market.
• Pricing pressures from healthcare providers and insurers.
• Technological obsolescence and the emergence of disruptive technologies.
• Product liability claims and recalls.
• Regulatory changes and compliance requirements.

What Are the Growth Opportunities for DXCM?

• Expanding International Presence: DexCom has a significant opportunity to expand its presence in international markets, particularly in Europe and Asia. The increasing prevalence of diabetes in these regions, coupled with growing awareness of the benefits of CGM technology, creates a substantial market opportunity. By establishing strategic partnerships and tailoring its products to meet local needs, DexCom can drive significant revenue growth. This expansion could contribute to a 20% increase in international sales by 2028.
• Next-Generation CGM Systems: The development and launch of next-generation CGM systems, such as the DexCom G7, represents a major growth opportunity for the company. These advanced systems offer improved accuracy, ease of use, and connectivity, attracting a wider range of patients and healthcare providers. The G7's enhanced features could lead to a 15% increase in market share within the next two years, solidifying DexCom's leadership position.
• Integration with Digital Health Platforms: DexCom's Real-Time API enables the integration of its CGM data into various digital health applications and devices. This integration creates new opportunities for personalized diabetes management and improved patient engagement. By partnering with leading digital health companies, DexCom can expand its reach and offer comprehensive solutions to patients. This integration could drive a 10% increase in user engagement and data utilization by 2027.
• Expansion into New Therapeutic Areas: While DexCom primarily focuses on diabetes management, there is potential to expand its CGM technology into other therapeutic areas, such as obesity and metabolic disorders. Continuous monitoring of glucose levels can provide valuable insights into these conditions, enabling more effective treatment strategies. This expansion could open up new markets and revenue streams for DexCom, potentially contributing to a 5% increase in overall revenue by 2029.
• Strategic Partnerships and Acquisitions: DexCom can pursue strategic partnerships and acquisitions to accelerate its growth and expand its capabilities. Collaborating with complementary technology companies or acquiring innovative startups can enhance DexCom's product offerings and market reach. These partnerships could lead to the development of new solutions and the expansion into new markets, driving long-term growth and shareholder value. A successful acquisition could add 8% to the company's revenue within three years.

What Are DXCM's Competitive Advantages?

• Technological Innovation: DexCom's continuous glucose monitoring (CGM) systems are based on advanced sensor technology and data analytics, providing a competitive advantage.
• Brand Reputation: DexCom has established a strong brand reputation for accuracy, reliability, and ease of use in the CGM market.
• Regulatory Approvals: DexCom has obtained regulatory approvals from the FDA and other agencies, creating barriers to entry for competitors.
• Data Network Effects: The more users who adopt DexCom's CGM systems, the more valuable the data becomes for improving algorithms and personalized insights.

What Does DXCM Do?

DexCom, Inc., founded in 1999 and headquartered in San Diego, California, is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. The company's core mission is to improve the lives of people with diabetes by providing innovative and accurate glucose monitoring solutions. DexCom's flagship product, the DexCom G6, is an integrated CGM system that allows patients to track their glucose levels in real-time without the need for frequent finger sticks. This system provides valuable data to both patients and healthcare providers, enabling better diabetes management and improved health outcomes. DexCom has expanded its product line to include Dexcom ONE, designed as a direct replacement for finger stick blood glucose testing, and Dexcom Share, a remote monitoring system that allows caregivers to track a patient's glucose levels remotely. The company is also developing the Dexcom G7, a next-generation CGM system. DexCom markets its products directly to endocrinologists, physicians, and diabetes educators, ensuring that healthcare professionals are well-informed about the benefits of CGM technology. DexCom has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products, further demonstrating its commitment to innovation in diabetes care. DexCom has a market capitalization of $31.9B and employs 10,200 individuals.

What Products and Services Does DXCM Offer?

• Designs, develops, and commercializes continuous glucose monitoring (CGM) systems.
• Provides CGM systems for use by people with diabetes.
• Offers CGM systems for use by healthcare providers.
• Develops integrated CGM systems for diabetes management.
• Creates real-time APIs for integrating CGM data into digital health applications.
• Provides remote monitoring systems for caregivers.
• Develops next-generation CGM systems with improved accuracy and ease of use.

How Does DXCM Make Money?

• Sells continuous glucose monitoring (CGM) systems directly to patients and healthcare providers.
• Generates revenue from the sale of sensors and transmitters used with its CGM systems.
• Offers subscription-based services for data monitoring and analysis.
• Partners with digital health companies to integrate CGM data into their platforms.

What Industry Does DXCM Operate In?

DexCom operates in the medical device industry, specifically within the diabetes care market. The industry is characterized by increasing demand for advanced glucose monitoring solutions, driven by the rising prevalence of diabetes globally. The competitive landscape includes established medical device companies and emerging technology firms. The company's focus on innovation and patient-centric solutions gives it a competitive edge in this dynamic market.

Who Are DXCM's Key Customers?

• Individuals with diabetes who require continuous glucose monitoring.
• Endocrinologists and other healthcare professionals who treat patients with diabetes.
• Hospitals and clinics that provide diabetes care services.
• Caregivers who monitor the glucose levels of patients remotely.

Company Profile

DexCom, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Jacob Steven Leach. DXCM has traded publicly since 2005.

DexCom, Inc. Financial Trajectory

DexCom, Inc. (DXCM) reported $1.31B in revenue for Q2 FY2026, reflecting 9.8% growth compared to the prior quarter. The company recorded net income of $249.1M, with diluted EPS of $0.64. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, DXCM averaged $0.63 in diluted EPS.

How DexCom, Inc. Is Valued

DexCom, Inc. carries a market capitalization of $31.9B, placing it in the large-cap category. Analyst price targets span from $64.00 to $105.00, with a consensus of $89.71. At the current price of $84.51, that implies approximately 6% upside potential. Relative to its peer group, DXCM's quantitative score of 88/100 is above the peer average of 67/100.

Return on equity for DexCom, Inc. stands at 33.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 14.0%, showing how much profit it generates from its asset base. DXCM trades at a trailing price-to-earnings ratio of 32.63, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.5%, the inverse of the P/E and a quick read on earnings relative to price.

DexCom, Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 7.33 places it in the safe zone, indicating low near-term bankruptcy risk.

DexCom, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 5.9% above estimates on average.

Over the past six months, DexCom, Inc. insiders filed 49 SEC Form 4 transactions — 35 sales and 14 purchases. On net that is roughly 107K shares disposed (about $12.2M), a signal worth weighing alongside the fundamentals.

DXCM Financials

DXCM Latest News

DXCM Analyst Consensus

DXCM MoonshotScore

Latest DexCom, Inc. Analysis

Common Questions About DXCM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources